Studies on the inhibition of AmpC and other beta-lactamases by cyclic boronates.
Cahill, S.T., Tyrrell, J.M., Navratilova, I.H., Calvopina, K., Robinson, S.W., Lohans, C.T., McDonough, M.A., Cain, R., Fishwick, C.W.G., Avison, M.B., Walsh, T.R., Schofield, C.J., Brem, J.(2019) Biochim Biophys Acta Gen Subj 1863: 742-748
- PubMed: 30738906 
- DOI: https://doi.org/10.1016/j.bbagen.2019.02.004
- Primary Citation of Related Structures:  
6I30 - PubMed Abstract: 
The β-lactam antibiotics represent the most successful drug class for treatment of bacterial infections. Resistance to them, importantly via production of β-lactamases, which collectively are able to hydrolyse all classes of β-lactams, threatens their continued widespread use. Bicyclic boronates show potential as broad spectrum inhibitors of the mechanistically distinct serine- (SBL) and metallo- (MBL) β-lactamase families.
Organizational Affiliation: 
Department of Chemistry, University of Oxford, Chemistry Research Laboratory, 12 Mansfield Road, Oxford OX1 3TA, United Kingdom.